Skip to main content
. 2021 Mar 8;5(5):1483–1489. doi: 10.1182/bloodadvances.2020002982

Table 2.

Treatment details and toxicity

R-CEOP R-CHOP
Anthracycline received
 No anthracycline 47 (67)
 Partial anthracycline 23 (33)
Reason for etoposide substitution
 Cardiac contraindication 63 (90)
 Prior exposure 5 (7)
 Other comorbidities 2 (3)
Treatment tolerance
 Percentage of deaths due to toxicity 3 (4) 5 (4)
 Completed planned treatment 54 (78) 110 (79)

Data are presented as n (%) of patients.